Search drugs and targets

You are searching for: ICD9: 331

Disease Entry Cognitive impairment
ICD9 ICD-9: 331
ICD10 ICD-10: F06.7
Target Neuronal acetylcholine receptor alpha-7 (CHRNA7) Target Info Successful
BNC375 Drug Info Phase 1
Disease Entry Cognitive impairment
ICD9 ICD-9: 331.83
ICD10 ICD-10: F06.7
Target Amyloid beta A4 protein (APP) Target Info Successful
CT-003230 Drug Info Investigative
Target Gamma-secretase (GS) Target Info Successful
CHF-5074 Drug Info Phase 2
Disease Entry Alzheimer disease
ICD9 ICD-9: 331
ICD10 ICD-10: G30, G30.9
Target Cathepsin B (CTSB) Target Info Preclinical
PMID27998201-Compound-22 Drug Info Patented
PMID27998201-Compound-2 Drug Info Patented
SD1002 Drug Info Preclinical
Z-Phe-Ala-diazomethylketone Drug Info Preclinical
SD1003 Drug Info Preclinical
Target Opioid receptor sigma 1 (OPRS1) Target Info Successful
ANAVEX 2-73 Drug Info Phase 1
AVP-786 Drug Info Phase 3
ANAVEX 1-41 Drug Info Preclinical
Target Muscarinic acetylcholine receptor M1 (CHRM1) Target Info Successful
ANAVEX 2-73 Drug Info Phase 1
Talsaclidine fumarate Drug Info Discontinued in Phase 2
MCD-386 Drug Info Phase 1
Alvameline Drug Info Terminated
TAK-071 Drug Info Phase 1
Target 5-HT 1A receptor (HTR1A) Target Info Successful
RP5063 Drug Info Phase 2
Eltoprazine Drug Info Phase 3
Neu-P11 Drug Info Phase 2
AV-965 Drug Info Phase 1
Target Dopamine D2 receptor (D2R) Target Info Successful
RP5063 Drug Info Phase 2
Dihydroergotoxine Drug Info Approved
Target Dopamine D3 receptor (D3R) Target Info Successful
RP5063 Drug Info Phase 2
Target Dopamine D4 receptor (D4R) Target Info Successful
RP5063 Drug Info Phase 2
Target 5-HT 2A receptor (HTR2A) Target Info Successful
RP5063 Drug Info Phase 2
Nuplazid Drug Info Phase 2
Target Serotoninnorepinephrinedopamine reuptake (SNDR) Target Info Successful
RP5063 Drug Info Phase 2
Target Histamine H1 receptor (H1R) Target Info Successful
RP5063 Drug Info Phase 2
Target 5-HT 7 receptor (HTR7) Target Info Clinical trial
RP5063 Drug Info Phase 2
Target 5-HT 2C receptor (HTR2C) Target Info Successful
Eltoprazine Drug Info Phase 3
Nuplazid Drug Info Phase 2
Target 5-HT 1B receptor (HTR1B) Target Info Successful
Eltoprazine Drug Info Phase 3
Target 5-HT 6 receptor (HTR6) Target Info Clinical trial
AVN 101 Drug Info Phase 2
AVN 322 Drug Info Phase 2
SYN-120 Drug Info Phase 2
SB-742457 Drug Info Phase 3
SUVN-502 Drug Info Phase 2
ABT-354 Drug Info Phase 1
PF-05212377 Drug Info Phase 2
SAM-531 Drug Info Phase 2
AVN-322 Drug Info Phase 1
Target Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) Target Info Clinical trial
Myo-inositol Drug Info Phase 2
Target Amyloid beta A4 protein (APP) Target Info Successful
Myo-inositol Drug Info Phase 2
EB-101 Drug Info Phase 1/2
ALZ-801 Drug Info Phase 2
Crenezumab Drug Info Phase 3
T-817MA Drug Info Phase 2
PF-05236812 Drug Info Discontinued in Phase 1
Affitope AD-02 Drug Info Discontinued in Phase 2
Mimovax Drug Info Investigative
123I-DRM-106 Drug Info Investigative
ARC-069 Drug Info Investigative
A-887755 Drug Info Investigative
ANA-5 Drug Info Investigative
TKP-1001 Drug Info Investigative
ACI-636 Drug Info Investigative
ARN-2966 Drug Info Investigative
SEN-1500 Drug Info Investigative
Anticalin Drug Info Investigative
EDN-OL1 Drug Info Investigative
ACU-0101979 Drug Info Investigative
RECALL-VAX Drug Info Investigative
SP-08 Drug Info Investigative
Abloid Drug Info Investigative
KMS-88009 Drug Info Investigative
KNX-Monoclonal204 Drug Info Investigative
DBT-1339 Drug Info Investigative
Gamma-secretase modulators Drug Info Investigative
11A1 Drug Info Investigative
Turmeric extracts Drug Info Investigative
BAN-2203 Drug Info Investigative
ELND-007 Drug Info Investigative
VK-11 Drug Info Investigative
AD-0802 Drug Info Investigative
AAB-002 Drug Info Phase 0
AAB-003/PF-05236812 Drug Info Phase 1
Anti-N3pG-Abeta antibody Drug Info Phase 1
DWP-09031 Drug Info Phase 1
SAR228810 Drug Info Phase 1
11C-AZD-2184 Drug Info Phase 1
Affitope AD-01 Drug Info Phase 1
11C-6-Me-BTA-1 Drug Info Phase 1
ACI-24 Drug Info Phase 1/2
FRM-0962 Drug Info Phase 2
Lecanemab Drug Info Approved
Ponezumab Drug Info Phase 2
UB-311 Drug Info Phase 2
GSK933776A Drug Info Phase 2
NIC5-15 Drug Info Phase 2
AN-1792 Drug Info Phase 2
CAD-106 Drug Info Phase 2/3
Solanezumab Drug Info Phase 3
Aducanumab Drug Info Approved
Tramiprosate Drug Info Phase 3
Bapineuzumab Drug Info Phase 3
Gantenerumab Drug Info Phase 3
NI-101 Drug Info Phase 3
Pepticlere Drug Info Preclinical
ALZT-OP1 Drug Info Phase 3
LY3372993 Drug Info Phase 1
ACU193 Drug Info Phase 1
BEY2153 Drug Info Phase 1
ANVS301 Drug Info Phase 1
Trontinemab Drug Info Phase 2
AD-35 Drug Info Phase 2
ABBV-916 Drug Info Phase 2
Donanemab Drug Info Phase 3
GV-971 Drug Info Phase 3
Target Serotonin transporter (SERT) Target Info Successful
AVP-786 Drug Info Phase 3
Target Microtubule-associated protein tau (MAPT) Target Info Clinical trial
PBT-2 Drug Info Phase 2
LMT-X Drug Info Phase 3
BIIB092 Drug Info Phase 2
PTI-80 Drug Info Phase 1
Tau-binding PET tracer Drug Info Phase 2
LY3303560 Drug Info Phase 1
RG6100 Drug Info Phase 2
TRx0237 Drug Info Phase 3
PRX-005 Drug Info Phase 1
BEY2153 Drug Info Phase 1
Lu AF87908 Drug Info Phase 1
APNmAb005 Drug Info Phase 1
E2814 Drug Info Phase 2/3
JNJ-63733657 Drug Info Phase 2
Bepranemab Drug Info Phase 2
Semorinemab Drug Info Phase 2
Target Macrophage colony-stimulating factor 1 receptor (CSF1R) Target Info Successful
Pexidartinib Drug Info Approved
Target Tyrosine-protein kinase Kit (KIT) Target Info Successful
Pexidartinib Drug Info Approved
Target Fms-like tyrosine kinase 3 (FLT-3) Target Info Successful
Pexidartinib Drug Info Approved
MK-2461 Drug Info Phase 1/2
Target Peroxisome proliferator-activated receptor gamma (PPAR-gamma) Target Info Successful
Rosiglitazone XR Drug Info Approved
Thiazolidinedione Drug Info Approved
T3D-959 Drug Info Phase 1/2
T3D-959 Drug Info Phase 2
Target Calcium-activated potassium channel (KCN) Target Info Successful
ICA-17043 Drug Info Phase 2
Target Calcium-activated potassium channel KCa3.1 (KCNN4) Target Info Clinical trial
ICA-17043 Drug Info Phase 2
Target Phosphodiesterase 9 (PDE9) Target Info Clinical trial
BI-409306 Drug Info Phase 2
PF-4447943 Drug Info Phase 2
E2027 Drug Info Phase 2
Target 5-HT 1D receptor (HTR1D) Target Info Successful
Neu-P11 Drug Info Phase 2
Target Melatonin receptor type 1A (MTNR1A) Target Info Successful
Neu-P11 Drug Info Phase 2
Target Metabotropic glutamate receptor 3 (mGluR3) Target Info Clinical trial
Oleoyl-estrone Drug Info Phase 2
MP-101 Drug Info Phase 2
Target Metabotropic glutamate receptor 2 (mGluR2) Target Info Clinical trial
Oleoyl-estrone Drug Info Phase 2
MP-101 Drug Info Phase 2
Target Acetylcholinesterase (AChE) Target Info Successful
R-phenserine Drug Info Phase 2
Tacrine Drug Info Approved
Donepezil Drug Info Approved
Galantamine Drug Info Approved
Rivastigmine Drug Info Approved
NP-61 Drug Info Discontinued in Phase 1
Zanapezil Drug Info Discontinued in Phase 3
Ladostigil Drug Info Phase 2
Methanesulfonyl fluoride Drug Info Phase 2
INM-176 Drug Info Phase 3
(-)-Phenserine Drug Info Phase 3
SPH-1285 Drug Info Preclinical
ABS-301 Drug Info Terminated
NP-7557 Drug Info Terminated
MF268 Drug Info Terminated
F-3796 Drug Info Terminated
FR-152558 Drug Info Terminated
MF-8615 Drug Info Terminated
CI-1002 Drug Info Terminated
Ro-46-5934 Drug Info Terminated
CPC-212 Drug Info Phase 1
CPC-250 Drug Info Phase 1
AD-35 Drug Info Phase 2
Target MAP kinase p38 (MAPK12) Target Info Successful
VX-745 Drug Info Phase 2
Target Stress-activated protein kinase 2a (p38 alpha) Target Info Clinical trial
VX-745 Drug Info Phase 2
Target Stress-activated protein kinase 2b (p38 beta) Target Info Clinical trial
VX-745 Drug Info Phase 2
Target Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) Target Info Clinical trial
ARC029 Drug Info Phase 3
Target Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) Target Info Successful
ARC029 Drug Info Phase 3
Target Histamine H3 receptor (H3R) Target Info Successful
PMID29334795-Compound-22 Drug Info Patented
AZD-5213 Drug Info Phase 2
SAR-110894 Drug Info Phase 2
S-38093 Drug Info Phase 2
GT-2016 Drug Info Terminated
Target DNA synthesis (DNA synth) Target Info Successful
acelarin Drug Info Phase 3
Target Beta-secretase (BACE) Target Info Clinical trial
E-2609 Drug Info Phase 3
verubecestat Drug Info Phase 3
AZD-3839 Drug Info Phase 1
CTS-21166 Drug Info Phase 1
HPP-854 Drug Info Phase 1
LY-2811376 Drug Info Phase 1
RG7129 Drug Info Phase 1
LY2886721 Drug Info Phase 2
AZD3293 Drug Info Phase 2/3
JNJ-54861911 Drug Info Phase 2/3
SCH-1359113 Drug Info Preclinical
DNP-004089 Drug Info Terminated
LY3202626 Drug Info Phase 2
Lanabecestat Drug Info Phase 3
Target Beta-secretase 1 (BACE1) Target Info Clinical trial
E-2609 Drug Info Phase 3
verubecestat Drug Info Phase 3
AMG520 Drug Info Phase 2/3
Target GABA(A) receptor alpha-5 (GABRA5) Target Info Successful
Basmisanil Drug Info Phase 2
Target Tau protein aggregation (TauA) Target Info Clinical trial
LMT-X Drug Info Phase 3
Target TAR DNA binding protein 43 (TARDBP) Target Info Clinical trial
LMT-X Drug Info Phase 3
Target Prostaglandin G/H synthase 2 (COX-2) Target Info Successful
Eicosapentaenoic acid/docosa-hexaenoic acid Drug Info Approved
GR-253035 Drug Info Discontinued in Phase 1
Target Prostaglandin G/H synthase 1 (COX-1) Target Info Successful
Eicosapentaenoic acid/docosa-hexaenoic acid Drug Info Approved
Target Glutamate receptor AMPA (GRIA) Target Info Successful
CX-717 Drug Info Phase 2
L-698544 Drug Info Terminated
Dihydroergotoxine Drug Info Approved
IPENOXAZONE Drug Info Discontinued in Phase 2
S-18986 Drug Info Discontinued in Phase 2
Coluracetam Drug Info Phase 2
Mibampator Drug Info Phase 2
CX-1501 Drug Info Preclinical
TPT-43 Drug Info Preclinical
GYKI-52466 Drug Info Terminated
NS-377 Drug Info Terminated
IDRA-21 Drug Info Terminated
Target N-methyl-D-aspartate receptor (NMDAR) Target Info Successful
L-698544 Drug Info Terminated
AXS-05 Drug Info Phase 3
Memantine Drug Info Approved
ASP-0777 Drug Info Phase 1
IDRA-21 Drug Info Terminated
NBXT-001+Nobilis inhalation device Drug Info Phase 1
SAGE-718 Drug Info Phase 2
Target Glutamate receptor ionotropic NMDA 2B (NMDAR2B) Target Info Successful
L-698544 Drug Info Terminated
Target Glutamate receptor ionotropic NMDA 2A (NMDAR2A) Target Info Successful
L-698544 Drug Info Terminated
Target Glutamate receptor ionotropic NMDA 1 (NMDAR1) Target Info Successful
L-698544 Drug Info Terminated
Target Estrogen receptor beta (ESR2) Target Info Successful
AUS-131 Drug Info Phase 2
Target Protein kinase C epsilon (PRKCE) Target Info Successful
Bryostatin-1 Drug Info Phase 2
Target Insulin receptor (INSR) Target Info Successful
Mitoglitazone Drug Info Phase 2
DM-99 Drug Info Phase 2
Target Mitochondrial protein unspecific (MP) Target Info Clinical trial
Mitoglitazone Drug Info Phase 2
Target Lipid peroxidation (LPO) Target Info Clinical trial
T-817MA Drug Info Phase 2
Target Advanced glycosylation end product receptor (AGER) Target Info Clinical trial
PF-4494700 Drug Info Phase 3
TTP-4000 Drug Info Phase 1
TTP-448 Drug Info Phase 2
Target Heat shock protein 90 alpha (HSP90A) Target Info Successful
PU-AD Drug Info Phase 1
Target Gamma-secretase subunit APH-1A/1B (APH-1) Target Info Patented-recorded
PMID28350212-Compound-18 Drug Info Patented
PMID28350212-Compound-19 Drug Info Patented
PMID28350212-Compound-20 Drug Info Patented
Target Monoamine oxidase type B (MAO-B) Target Info Successful
Schiff base compound 1 Drug Info Patented
Schiff base compound 2 Drug Info Patented
SL-25.1188 Drug Info Discontinued in Phase 1
EVT-301 Drug Info Discontinued in Phase 1
RG1577 Drug Info Phase 2
Ladostigil Drug Info Phase 2
Milacemide Drug Info Terminated
EVT302 Drug Info Phase 2
ORY-2001 Drug Info Phase 2
Target Monoamine oxidase type A (MAO-A) Target Info Successful
Schiff base compound 1 Drug Info Patented
Ladostigil Drug Info Phase 2
Bifemelane Drug Info Terminated
Target Tropomyosin-related kinase A (TrkA) Target Info Successful
Thiadiazolyl carboxamide derivative 1 Drug Info Patented
MIM-D3 Drug Info Phase 3
Target Monoamine oxidase (MAO) Target Info Successful
Ergoloid mesylate Drug Info Approved
Target Factor XI messenger RNA (F11 mRNA) Target Info Clinical trial
alpha-ketothiazole analogue 36 Drug Info Clinical trial
Target P2X purinoceptor 7 (P2RX7) Target Info Clinical trial
JNJ-479655 Drug Info Clinical trial
Target Prostaglandin F2-alpha receptor (PTGFR) Target Info Successful
bimatoprost (free acid form) Drug Info Clinical trial
Target Factor XII messenger RNA (FA12 mRNA) Target Info Clinical trial
methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate Drug Info Clinical trial
Target Glycogen synthase kinase-3 beta (GSK-3B) Target Info Clinical trial
AZD-1080 Drug Info Discontinued in Phase 1
SAN-61 Drug Info Terminated
Target Cytokine receptor unspecific (CRF) Target Info Clinical trial
VP-025 Drug Info Discontinued in Phase 1
Target Nicotinic acetylcholine receptor (nAChR) Target Info Successful
SIB-1553A Drug Info Discontinued in Phase 2
ABT-418 Drug Info Discontinued in Phase 2
NNC-90-0270 Drug Info Terminated
Target Neuronal acetylcholine receptor beta-4 (CHRNB4) Target Info Clinical trial
SIB-1553A Drug Info Discontinued in Phase 2
Target Neuronal acetylcholine receptor alpha-4 (CHRNA4) Target Info Successful
ABT-418 Drug Info Discontinued in Phase 2
Target Neuronal acetylcholine receptor beta-2 (CHRNB2) Target Info Clinical trial
ABT-418 Drug Info Discontinued in Phase 2
Target Neuronal acetylcholine receptor alpha-7 (CHRNA7) Target Info Successful
AZD0328 Drug Info Discontinued in Phase 2
EVP-4473 Drug Info Investigative
AZD-6319 Drug Info Investigative
AQW-051 Drug Info Phase 2
Target GABA(A) receptor gamma-3 (GABRG3) Target Info Successful
UC-1011 Drug Info Investigative
ZK-91296 Drug Info Terminated
RU-33965 Drug Info Terminated
ZK-93426 Drug Info Terminated
Target Leptin receptor (LEPR) Target Info Successful
Leptin Drug Info Investigative
Target C-C chemokine receptor type 2 (CCR2) Target Info Clinical trial
RAP-310 Drug Info Investigative
Target Interleukin-1 beta (IL1B) Target Info Successful
TT-301 Drug Info Phase 1
Target Prostaglandin E synthase (PTGES) Target Info Clinical trial
AAD-2004 Drug Info Phase 1
Target 5-HT 4 receptor (HTR4) Target Info Successful
PF-04995274 Drug Info Phase 1
TD-8954 Drug Info Phase 2
SUVN-D4010 Drug Info Phase 1
Target Calpain-2 (CAPN2) Target Info Clinical trial
ABT-957 Drug Info Phase 1
MDL-28170 Drug Info Terminated
Target Synuclein alpha (SNCA) Target Info Clinical trial
Posiphen R-phenserine Drug Info Phase 1
Target Neural cell adhesion molecule (NCAM) Target Info Clinical trial
FGLL Drug Info Phase 1
Target Cholinesterase (BCHE) Target Info Successful
Protexia Drug Info Phase 1
JES-9501 Drug Info Phase 1
(-)-Phenserine Drug Info Phase 3
RVT-103+RVT-104 Drug Info Phase 1
Target Gamma-secretase (GS) Target Info Successful
SPI-014 Drug Info Phase 1
Begacestat Drug Info Phase 1
E2012 Drug Info Phase 1
E-2212 Drug Info Phase 1
GSI-136 Drug Info Phase 1
MK-0752 Drug Info Phase 2
BMS-708163 Drug Info Phase 2
CHF-5074 Drug Info Phase 2
NGP 555 Drug Info Phase 1
PF-06648671 Drug Info Phase 1
PF-06648671 Drug Info Phase 1
Target Metabotropic glutamate receptor 5 (mGluR5) Target Info Clinical trial
MK-3328 Drug Info Phase 1
BMS-984923 Drug Info Phase 1
BMS-984923 Drug Info Phase 1
Target Nerve growth factor (NGF) Target Info Clinical trial
NsG-0202 Drug Info Phase 1
CERE-110 Drug Info Phase 2
Nerve growth factor Drug Info Terminated
Target Platelet-activating factor acetylhydrolase (PLA2G7) Target Info Clinical trial
GSK2647544 Drug Info Phase 1
Target Plasminogen activator inhibitor (PAI) Target Info Clinical trial
Aleplasinin Drug Info Phase 1
Target Translocator protein (TSPO) Target Info Successful
18F-FEDAA-1106 Drug Info Phase 1
Target Vascular endothelial growth factor receptor 3 (FLT-4) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Tyrosine-protein kinase Mer (MERTK) Target Info Clinical trial
MK-2461 Drug Info Phase 1/2
Target Proto-oncogene c-Met (MET) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Fibroblast growth factor receptor 1 (FGFR1) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Platelet-derived growth factor receptor beta (PDGFRB) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Vascular endothelial growth factor receptor 2 (KDR) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target VEGFR1 messenger RNA (VEGFR1 mRNA) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Fibroblast growth factor receptor 3 (FGFR3) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target NT-3 growth factor receptor (TrkC) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target BDNF/NT-3 growth factors receptor (TrkB) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Fibroblast growth factor receptor 2 (FGFR2) Target Info Successful
MK-2461 Drug Info Phase 1/2
Target Macrophage-stimulating protein receptor (RON) Target Info Clinical trial
MK-2461 Drug Info Phase 1/2
Target Peroxisome proliferator-activated receptor delta (PPARD) Target Info Clinical trial
T3D-959 Drug Info Phase 1/2
T3D-959 Drug Info Phase 2
Target Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) Target Info Successful
AZD-1446 Drug Info Phase 2
Target Glutathione-dependent PGD synthase (HPGDS) Target Info Successful
HF-0220 Drug Info Phase 2
Target Adrenergic receptor alpha-2C (ADRA2C) Target Info Successful
ORM-12741 Drug Info Phase 2
F-14413 Drug Info Terminated
Target Somatostatin receptor (SSTR) Target Info Clinical trial
FK-962 Drug Info Phase 2
Target Inhibitor of nuclear factor kappa-B kinase beta (IKKB) Target Info Clinical trial
IMD-1041 Drug Info Phase 2
Target Retinoic acid receptor beta (RARB) Target Info Successful
Tamibarotene Drug Info Phase 3
Target Retinoic acid receptor alpha (RARA) Target Info Clinical trial
Tamibarotene Drug Info Phase 3
Target Plasminogen (PLG) Target Info Successful
Plasminogen Drug Info Phase 2/3
Target Synaptic vesicle amine transporter (SLC18A2) Target Info Successful
AV 133 Drug Info Phase 3
Target Muscarinic acetylcholine receptor M2 (CHRM2) Target Info Successful
BIBN-140 Drug Info Terminated
Sch-57790 Drug Info Terminated
BIBN-99 Drug Info Terminated
Alvameline Drug Info Terminated
Target Muscarinic acetylcholine receptor (CHRM) Target Info Successful
A-72055 Drug Info Terminated
Target Protease unspecific (PRO) Target Info Successful
CEP-431 Drug Info Terminated
Target Somatostatin receptor type 4 (SSTR4) Target Info Clinical trial
FR-121196 Drug Info Terminated
Target Somatostatin receptor type 2 (SSTR2) Target Info Successful
FR-121196 Drug Info Terminated
Target Somatostatin receptor type 3 (SSTR3) Target Info Successful
FR-121196 Drug Info Terminated
Target Somatostatin receptor type 5 (SSTR5) Target Info Successful
FR-121196 Drug Info Terminated
Target Somatostatin receptor type 1 (SSTR1) Target Info Successful
FR-121196 Drug Info Terminated
Target Muscarinic acetylcholine receptor M5 (CHRM5) Target Info Successful
RS 86 Drug Info Terminated
Target Glutamate receptor AMPA 1 (GRIA1) Target Info Successful
GYKI-52466 Drug Info Terminated
Target GPCR unspecific (GPCR) Target Info Discontinued
R-1315 Drug Info Terminated
Target Calcium channel unspecific (CaC) Target Info Successful
NS-649 Drug Info Terminated
Target Low-affinity nerve growth factor receptor (NGFR) Target Info Successful
BU-4514N Drug Info Terminated
CEP-427 Drug Info Terminated
LM11A-31 Drug Info Phase 1/2
LM11A-31 Drug Info Phase 1/2
Target Ras-related C3 botulinum toxin substrate 1 (RAC1) Target Info Literature-reported
EHT-1864 Drug Info Terminated
Target Angiotensin II receptor type-1 (AGTR1) Target Info Successful
RS-66252 Drug Info Terminated
Target Muscarinic acetylcholine receptor M3 (CHRM3) Target Info Successful
Alvameline Drug Info Terminated
Target P2Y purinoceptor 6 (P2RY6) Target Info Clinical trial
GC021109 Drug Info Phase 1
Target Filamin A (FLNA) Target Info Clinical trial
PTI-125 Drug Info Phase 1
PTI-125 Drug Info Phase 2
Target COVID-19 papain-like proteinase (PL-PRO) Target Info .
Tideglusib Drug Info Investigative
Target FMLP-related receptor I (FPR2) Target Info Literature-reported
humanin Drug Info Preclinical
Target N-formyl peptide receptor 3 (FPR3) Target Info Literature-reported
humanin Drug Info Preclinical
Target Phosphodiesterase 4D (PDE4D) Target Info Successful
BPN14770 Drug Info Phase 2
Target Sigma intracellular receptor 2 (TMEM97) Target Info Clinical trial
CT1812 Drug Info Phase 2
Target Receptor-interacting protein 1 (RIPK1) Target Info Clinical trial
DNL747 Drug Info Phase 1
DNL104 Drug Info Phase 1
Target Microtubule (MicroTu) Target Info Clinical trial
TPI-287 Drug Info Phase 2
Target Cathepsin L (CTSL) Target Info Clinical trial
SD1002 Drug Info Preclinical
Z-Phe-Ala-diazomethylketone Drug Info Preclinical
SD1003 Drug Info Preclinical
Target Alpha-secretase (ASE) Target Info Clinical trial
APH-1104 Drug Info Phase 1
ID1201 Drug Info Phase 2
APH-1105 Drug Info Phase 2
Target Telomerase reverse transcriptase (TERT) Target Info Clinical trial
AAV-hTERT Drug Info Phase 1
Target Amyloid precursor protein (APP) Target Info Literature-reported
SHR-1707 Drug Info Phase 1
Target Beta-N-acetylhexosaminidase (OGA) Target Info Clinical trial
BIIB113 Drug Info Phase 1
ASN51 Drug Info Phase 1
LY3372689 Drug Info Phase 2
Target ATP synthase (ATPS) Target Info Literature-reported
J147 Drug Info Phase 1
Target Myeloid cell surface antigen CD33 (CD33) Target Info Successful
AL003 Drug Info Phase 1
Target Cannabinoid receptor 2 (CB2) Target Info Successful
NTRX-07 Drug Info Phase 1
Target APP messenger RNA (APP mRNA) Target Info Clinical trial
ALN-APP Drug Info Phase 1
Target Triggering receptor expressed on monocytes 2 (TREM2) Target Info Clinical trial
DNL919 Drug Info Phase 1
AL002 Drug Info Phase 2
Target Ribosomal protein S6 kinase beta-1 (S6K1) Target Info Clinical trial
NNI-362 Drug Info Phase 1
Target Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) Target Info Clinical trial
Xanamem Drug Info Phase 1/2
Target Apolipoprotein E (APOE) Target Info Clinical trial
LX1001 Drug Info Phase 1/2
Target Hepatitis A virus cellular receptor 2 (TIM3) Target Info Clinical trial
TB006 Drug Info Phase 2
Target Phosphodiesterase 5 (PDE5) Target Info Clinical trial
AR1001 Drug Info Phase 3
Target Protein kinase C (PRKC) Target Info Clinical trial
Bryostatin-1 Drug Info Phase 2
Target Stress-activated protein kinase (p38) Target Info Clinical trial
MW150 Drug Info Phase 2
Target Soluble guanylate cyclase (GCS) Target Info Successful
CY6463 Drug Info Phase 2
Target Lysine-specific histone demethylase 1 (LSD) Target Info Clinical trial
ORY-2001 Drug Info Phase 2
Vafidemstat Drug Info Phase 2
Target Glucagon-like peptide 1 receptor (GLP1R) Target Info Successful
NLY01 Drug Info Phase 2
Semorinemab Drug Info Phase 2
Target HGF/Met signaling pathway (HGF/Met pathway) Target Info Successful
Fosgonimeton Drug Info Phase 2/3
Target Adrenergic receptor alpha-2A (ADRA2A) Target Info Successful
Guanfacine Drug Info Phase 3
Target Estrogen receptor (ESR) Target Info Successful
NE3107 Drug Info Phase 3
Disease Entry Alzheimer disease
ICD9 ICD-9: 331
ICD10 ICD-10: G30, G30.9
Target DNA topoisomerase II (TOP2) Target Info Successful
Tirapazamine Drug Info Phase 3
Disease Entry Alzheimer disease
ICD9 ICD-9: 331
ICD10 ICD-10: G30, G30.9
Target Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) Target Info Clinical trial
ARC029 Drug Info Phase 3
Target Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) Target Info Successful
ARC029 Drug Info Phase 3
Target Lipid peroxidation (LPO) Target Info Clinical trial
T-817MA Drug Info Phase 2
Target Amyloid beta A4 protein (APP) Target Info Successful
T-817MA Drug Info Phase 2
Myo-inositol Drug Info Phase 2
Target Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) Target Info Clinical trial
Myo-inositol Drug Info Phase 2

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.